Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells

Treatment options for TP53-mutated lymphoid tumors are very limited. In experimental models, TP53-mutated lymphomas were sensitive to direct inhibition of checkpoint kinase 1 (Chk1), a pivotal regulator of replication. We initially tested the potential of the highly specific Chk1 inhibitor SCH900776...

Descripción completa

Detalles Bibliográficos
Autores principales: Zemanova, Jana, Hylse, Ondrej, Collakova, Jana, Vesely, Pavel, Oltova, Alexandra, Borsky, Marek, Zaprazna, Kristina, Kasparkova, Marie, Janovska, Pavlina, Verner, Jan, Kohoutek, Jiri, Dzimkova, Marta, Bryja, Vitezslav, Jaskova, Zuzana, Brychtova, Yvona, Paruch, Kamil, Trbusek, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308713/
https://www.ncbi.nlm.nih.gov/pubmed/27556692
http://dx.doi.org/10.18632/oncotarget.11388

Ejemplares similares

Ejemplares similares